Abstract

This research aims to evaluate two new pharmaceuticals on the market. Rimegepant and Lasmiditan target the trigeminovascular system and respectively, are characterized in the gepant and ditan classes of pharmaceuticals. Based on a review of studies, Rimegepant was determined to be the advantageous acute treatment. This is not conclusive due to inequivalent comparison in sample size and amount of research completed. It is encouraged for additional research to be imposed before a conclusive determination of the advantageous acute treatment can be distinguished.

Thesis Completion

2020

Semester

Fall

Thesis Chair

Ahangari, Raheleh

Degree

Bachelor of Science (B.S.)

College

College of Medicine

Language

English

Access Status

Open Access

Release Date

12-1-2020

Share

COinS